ARSENALBIO
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs, and expanded market access.
ARSENALBIO
Industry:
Biotechnology Cloud Computing Life Science
Founded:
2019-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.arsenalbio.com
Total Employee:
101+
Status:
Active
Contact:
650-240-8844
Total Funding:
305 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
EcoPlant
EcoPlant is a cloud based platform.
Proscia
Proscia is a leader in digital and computational pathology solutions.
Quell Therapeutics
Quell Therapeutics is a cell therapy company
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Euclidean Capital
Euclidean Capital investment in Series B - ArsenalBio
Parker Institute for Cancer Immunotherapy
Parker Institute for Cancer Immunotherapy investment in Series B - ArsenalBio
Bristol Myers Squibb
Bristol Myers Squibb investment in Series B - ArsenalBio
Emerson Collective
Emerson Collective investment in Series B - ArsenalBio
Westlake Village BioPartners
Westlake Village BioPartners investment in Series B - ArsenalBio
Kleiner Perkins
Kleiner Perkins investment in Series B - ArsenalBio
Sixth Street
Sixth Street investment in Series B - ArsenalBio
University of California, San Francisco
University of California, San Francisco investment in Series B - ArsenalBio
Hitachi Ventures
Hitachi Ventures investment in Series B - ArsenalBio
SoftBank Vision Fund
SoftBank Vision Fund investment in Series B - ArsenalBio
Key Employee Changes
| Date | New article |
|---|---|
| 2021-07-19 | ArsenalBio Strengthens Leadership Team with the Appointment of W. Nicholas Haining, BM, BCh, as Chief Scientific Officer |
Official Site Inspections
http://www.arsenalbio.com Semrush global rank: 3.94 M Semrush visits lastest month: 3.18 K
- Host name: 151.101.194.159
- IP address: 151.101.194.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
